Drug products: Etosuximid 2care4, Etosuximid Ebb, Etosuximid Medartuum, Petnidan, Suxinutin®, Zarondan, Zarontin
ATC code: N03AD01
Randomized controlled trials of differences between men and women in effect and safety of ethosuximide are lacking. Women seem to have a lower clearance of ethosuximide than men, a difference that varies depending on dose.
The present evidence concerning differences between men and women is limited and do not motivate differentiation in dosing or treatment.
One study in patients treated with ethosuximide (20 boys/men, 26 girls/women; age 1.5-38 years) showed that plasma concentration increased more rapidly, relative to dose, in girls/women than in boys/men . Another study in young adults (12 men, 21 women), with half of the women on oral contraceptives, revealed a 27% lower clearance in women in general but no difference associated with use of oral contraceptives . No sex differentiation in dosing has been recommended by the manufacturer .
No studies with a clinically relevant sex analysis regarding the effects of ethosuximide have been found .
No studies with a clinically relevant sex analysis regarding adverse effects of ethosuximide have been found.
Regarding teratogenic aspects, please consult the Drugs and Birth Defects Database (in Swedish, Janusmed fosterpåverkan).
Date of litterature search: 2013-03-14
Reviewed by: Expertrådet för neurologiska sjukdomar, Ellen Vinge, Lars Lööf
Approved by: Mia von Euler